TRLV · Trulieve Cannabis Corp.
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Retail dispensaries | 240 | Q1 2026 | — |
| Rewards program members | 1M | Q1 2026 | — |
| branded product units sold | 50.1M | Full Year 2025 | — |
| gross margin | 60% | Full Year 2025 | — |
| retail locations | 233 | as of December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TRLV
this stock
Trulieve Cannabis Corp.
|
$1.62B | -2.9% | -0.4% | — | 0.9% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$53.40B | +7.2% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$51.20B | +6.2% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.17B | +0.5% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.7%
- Reported
- 45 of 6
- Top holder
- iA Global Asset Managemen…
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TRLV | +4.7% | -5.1% | +29.9% | -2.4% | -2.9% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | -0.8% | -8.3% | +18.6% | -5.5% | -15.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.